Inhibition of CDK4/6 As a Novel Therapeutic Option for Neuroblastoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2015 Jul 31

PMID 26225123

Citations 28

Authors

Ali Rihani

Jo Vandesompele

Frank Speleman

Tom Van Maerken

Affiliations

Soon will be listed here.

Abstract

Background: Neuroblastoma is a neural crest-derived tumor and is the most common cancer in children less than 1 year of age. We hypothesized that aberrations in genes that control the cell cycle could play an important role in the pathogenesis of neuroblastoma and could provide a tractable therapeutic target.

Methods: In this study, we screened 131 genes involved in cell cycle regulation at different levels by analyzing the effect of siRNA-mediated gene silencing on the proliferation of neuroblastoma cells.

Results: Marked reductions in neuroblastoma cellular proliferation were recorded after knockdown of CCND1 or PLK1. We next showed that pharmacological inhibition of cyclin D1 dependent kinases 4/6 (CDK4/6) with PD 0332991 (palbociclib) reduced the growth of neuroblastoma cell lines, induced G1 cell cycle arrest, and inhibited the cyclin D1-Rb pathway.

Conclusion: Selective inhibition of CDK4/6 using palbociclib may provide a new therapeutic option for treating neuroblastoma.

Citing Articles

CDKL3 is a targetable regulator of cell cycle progression in cancers.

Zhang H, Lin J, Zheng S, Ma L, Pang Z, Yin H J Clin Invest. 2024; 134(16).

PMID: 38963708 PMC: 11324297. DOI: 10.1172/JCI178428.

Immune microenvironment heterogeneity reveals distinct subtypes in neuroblastoma: insights into prognosis and therapeutic targets.

Yang Y, Li H, Zheng D, Li X, Liu H Aging (Albany NY). 2023; 15(22):13345-13367.

PMID: 38019470 PMC: 10713432. DOI: 10.18632/aging.205246.

Neuroblastoma in the Era of Precision Medicine: A Clinical Review.

Wahba A, Wolters R, Foster J Cancers (Basel). 2023; 15(19).

PMID: 37835416 PMC: 10571527. DOI: 10.3390/cancers15194722.

Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development.

Yuan Y, Alzrigat M, Rodriguez-Garcia A, Wang X, Sjoberg Bexelius T, Johnsen J Cancers (Basel). 2023; 15(18).

PMID: 37760568 PMC: 10527308. DOI: 10.3390/cancers15184599.

Treatment of High-Risk Neuroblastoma.

Krystal J, Foster J Children (Basel). 2023; 10(8).

PMID: 37628301 PMC: 10453838. DOI: 10.3390/children10081302.

References

Musgrove E . Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006; 24(1):13-9. DOI: 10.1080/08977190500361812. View

Simoes-Costa M, Bronner M . Insights into neural crest development and evolution from genomic analysis. Genome Res. 2013; 23(7):1069-80. PMC: 3698500. DOI: 10.1101/gr.157586.113. View

Ackermann S, Goeser F, Schulte J, Schramm A, Ehemann V, Hero B . Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res. 2010; 17(4):731-41. DOI: 10.1158/1078-0432.CCR-10-1129. View

Musgrove E, Caldon C, Barraclough J, Stone A, Sutherland R . Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11(8):558-72. DOI: 10.1038/nrc3090. View

Flaherty K, LoRusso P, DeMichele A, Abramson V, Courtney R, Randolph S . Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2011; 18(2):568-76. DOI: 10.1158/1078-0432.CCR-11-0509. View

Creevey L, Ryan J, Harvey H, Bray I, Meehan M, Khan A . MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 2013; 12:23. PMC: 3626575. DOI: 10.1186/1476-4598-12-23. View

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

Molenaar J, Ebus M, Koster J, Santo E, Geerts D, Versteeg R . Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene. 2010; 29(18):2739-45. DOI: 10.1038/onc.2010.21. View

Rader J, Russell M, Hart L, Nakazawa M, Belcastro L, Martinez D . Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22):6173-82. PMC: 3844928. DOI: 10.1158/1078-0432.CCR-13-1675. View

10.

Harper J, Goodrich D . Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997; 8(2):287-301. PMC: 276080. DOI: 10.1091/mbc.8.2.287. View

11.

Molenaar J, van Sluis P, Boon K, Versteeg R, Caron H . Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer. 2003; 36(3):242-9. DOI: 10.1002/gcc.10166. View

12.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

13.

Molenaar J, Ebus M, Koster J, van Sluis P, van Noesel C, Versteeg R . Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res. 2008; 68(8):2599-609. DOI: 10.1158/0008-5472.CAN-07-5032. View

14.

Diehl J, Cheng M, Roussel M, Sherr C . Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12(22):3499-511. PMC: 317244. DOI: 10.1101/gad.12.22.3499. View

15.

Grant G, Brooks 3rd L, Zhang X, Mahoney J, Martyanov V, Wood T . Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell. 2013; 24(23):3634-50. PMC: 3842991. DOI: 10.1091/mbc.E13-05-0264. View

16.

Rihani A, Van Maerken T, Pattyn F, Van Peer G, Beckers A, De Brouwer S . Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments. PLoS One. 2013; 8(8):e71776. PMC: 3743747. DOI: 10.1371/journal.pone.0071776. View

17.

Ismail I, Kang K, Lee H, Kim J, Sohn Y . Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol. 2007; 575(1-3):12-20. DOI: 10.1016/j.ejphar.2007.07.039. View

18.

Lapenna S, Giordano A . Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009; 8(7):547-66. DOI: 10.1038/nrd2907. View

19.

Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M . Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 2011; 71(4):1385-95. DOI: 10.1158/0008-5472.CAN-10-2484. View

20.

Schwartz G, LoRusso P, Dickson M, Randolph S, Shaik M, Wilner K . Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011; 104(12):1862-8. PMC: 3111206. DOI: 10.1038/bjc.2011.177. View